Capricor Therapeutics Claims Nippon Shinyaku Delays Duchenne Drug Rollout

Capricor Therapeutics has publicly accused Nippon Shinyaku and its U.S. subsidiary of mishandling the rollout of a treatment aimed at Duchenne muscular dystrophy.

The company expresses frustration over what it perceives as delays in the introduction of this critical therapy.

These allegations highlight ongoing tensions in the pharmaceutical sector, particularly concerning the timely delivery of treatments for serious conditions.